{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:29:55Z","timestamp":1792718995239,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ymgmr.2024.101084","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T04:16:35Z","timestamp":1713845795000},"page":"101084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program"],"prefix":"10.1016","volume":"39","author":[{"given":"Cary O.","family":"Harding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sacharow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Vockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto T.","family":"Zori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleigh","family":"Bulloch Whitehall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Lilienstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew G.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara K.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2024.101084_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymgmr.2024.101084_bb0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/87565641.2016.1243109","article-title":"Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria","volume":"41","author":"Bilder","year":"2016","journal-title":"Dev. Neuropsychol."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","article-title":"The complete European guidelines on phenylketonuria: diagnosis and treatment","volume":"12","author":"van Wegberg","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.05.017","article-title":"Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence","volume":"101","author":"Enns","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","article-title":"Adherence to clinic recommendations among patients with phenylketonuria in the United States","volume":"120","author":"Jurecki","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ymgme.2014.11.011","article-title":"A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria","volume":"114","author":"Burton","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0040","author":"BioMarin Pharmaceutical Inc"},{"key":"10.1016\/j.ymgmr.2024.101084_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173269","article-title":"Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria","volume":"12","author":"Bell","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2024.101084_bb0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymgmr.2024.101084_bb0055","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgmr.2024.101084_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2018.03.003","article-title":"Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation phase 3 clinical trial","volume":"124","author":"Harding","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108122","article-title":"Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: analysis of phase 3 clinical trial data","volume":"141","author":"Rohr","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0080","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41436-018-0403-z","article-title":"Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria","volume":"21","author":"Longo","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2021.09.006","article-title":"Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses","volume":"134","author":"Aryal","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2019.05.006","article-title":"Pegvaliase: immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy","volume":"128","author":"Hausmann","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101084_bb0095","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/cts.13043","article-title":"Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria","volume":"14","author":"Qi","year":"2021","journal-title":"Clin. Transl. Sci."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T20:10:17Z","timestamp":1723147817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426924000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":19,"alternative-id":["S2214426924000375"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101084","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101084"}}